Free tool
FAERS Monitor: Saxenda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206321 or its brand name (Saxenda, Liraglutide). Reports on generic versions are filed under their own applications.
Reports
10,421
Serious
5,921
57% of reports
Hospitalization
2,523
Death reported
297
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,390
- vomiting809
- diarrhoea566
- drug ineffective546
- off label use518
- weight increased447
- fatigue439
- headache435
- constipation408
- dyspnoea408
- anxiety344
- weight loss poor339
- condition aggravated323
- decreased appetite312
- dizziness312
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 14 |
| 2011 | 19 |
| 2012 | 30 |
| 2013 | 40 |
| 2014 | 59 |
| 2015 | 359 |
| 2016 | 1,262 |
| 2017 | 1,041 |
| 2018 | 616 |
| 2019 | 805 |
| 2020 | 719 |
| 2021 | 799 |
| 2022 | 814 |
| 2023 | 1,040 |
| 2024 | 863 |
| 2025 | 909 |
| 2026 | 1,029 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,738 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| weight loss poorSignal | 339 | 143.2 | 128.5 | 44,590 |
| weight increasedSignal | 447 | 4.0 | 3.7 | 1,026 |
| constipationSignal | 408 | 3.8 | 3.4 | 839 |
| nauseaSignal | 1,390 | 3.5 | 3.4 | 2,637 |
| vomitingSignal | 809 | 3.5 | 3.3 | 1,455 |
| decreased appetiteSignal | 312 | 2.7 | 2.4 | 339 |
| anxietySignal | 344 | 2.4 | 2.2 | 295 |
| condition aggravatedSignal | 323 | 2.1 | 1.9 | 199 |
| diarrhoea | 566 | 1.8 | 1.6 | 195 |
| dyspnoea | 408 | 1.5 | 1.3 | 59 |
| headache | 435 | 1.4 | 1.3 | 51 |
| dizziness | 312 | 1.3 | 1.1 | 17 |
| off label use | 518 | 1.2 | 1.1 | 17 |
| fatigue | 439 | 1.1 | 1.0 | 7 |
| drug ineffective | 546 | 0.8 | 0.8 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.